Navigation Links
WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
Date:1/3/2008

SHANGHAI, China, Jan. 3 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services is pleased to announce today that it has promoted Mr. Edward Hu from Executive Vice President of Operations to Chief Operating Officer.

Prior to joining WuXi PharmaTech in August 2007, Mr. Hu was a senior vice president and Chief Operating Officer at Tanox, Inc., a NASDAQ listed company later acquired by Genentech, Inc. He also worked for Biogen Idec as a business planning manager and for Merck as a senior financial analyst. In the last few months as Executive Vice President of Operations at WuXi PharmaTech, Mr. Hu took many initiatives to strengthen the company's operations and corporate development; he is also instrumental in leading the AppTec acquisition.

"We are very happy to promote Ed to give him more responsibilities, as Ed has quickly demonstrated his leadership capabilities and ability to contribute to the company. Ed will be based in the US to lead the integration of AppTec after the deal is closed," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

Mr. Hu received his MBA and MS in Chemistry from Carnegie Mellon University, Pittsburgh, Pennsylvania.

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two s
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
2. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
3. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
4. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
5. WuXi PharmaTech Announces Second Quarter 2007 Results
6. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
7. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
8. Enzyme promotes fat formation
9. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
10. Edwards Lifesciences Forecasts Strong Growth in 2008
11. Marshall Edwards, Inc. to Present at BIO Investor Forum 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual ... Solutions as number 1,361 in growth for the three years through 2014. Being named ... fastest-growing privately held organizations in the country. , “We are thrilled to make ...
(Date:8/27/2015)... ... August 27, 2015 , ... Proove Biosciences, ... data on the relationship of genetics and hypertension at the International Academy ... in Vancouver, British Columbia, Canada. The event, which boasts an extensive overview of ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... Calif., May 18, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: ... Officer of BioMarin, will present a company update at the ... 25, 2011 at 9:30 a.m. GMT.   Interested ... call via the investor section of the BioMarin website, ...
... Northwest Biotherapeutics (OTC Bulletin Board: NWBO ) ... production of DCVax®-L for brain cancer, for clinical trials ... largest applied research foundation in Europe, with a staff ... others dedicated to practical applications and commercialization of research ...
... presented today show that RAPAFLO(R) (silodosin) significantly reduced ... pain syndrome (CP/CPPS).  In the study presented at ... RAPAFLO(R) also significantly improved urinary symptoms as well ... pelvic pain syndrome (CP/CPPS) is a common condition ...
Cached Biology Technology:BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference 2Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe 2Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe 3Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe 4Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 2Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 3Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 4Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 5Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 6
(Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
(Date:7/31/2015)... de 2015 La 10 th International Conference ... de BGI del 22 al 25 de octubre de 2015 en ... año, la conferencia celebra su décimo aniversario. Desde su inauguración ... de las reuniones anuales más influyentes del mundo en el ... dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/31/2015)... -- The 10 th International Conference on Genomics (ICG-10, ... 2015, in Shenzhen , China ... th anniversary this year. Since its inauguration in 2006, ... meetings in the ,omics, fields, and is one of the ... ICG-10 focuses on recent breakthroughs and advances in ,omics, research ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... (April 6, 2009) Cell Press, an imprint of Elsevier, ... well as Current Biology and The American ... Library Association,s (SLA) Top 100 Journals in Biology and Medicine ... compiled by the 680-plus members of the SLA,s Biomedical and ...
... experimental vaccine that triggers the patient,s immune system to ... promise for the treatment of early lung cancer. ... the vaccine called MAGE-A3 Antigen-Specific Cancer Immunotherapeutic, which is ... Rush is one of only five hospitals in Illinois ...
... systems for splitting water into hydrogen and oxygen, driven ... science today, underpinning the long term potential of hydrogen ... exist today are very inefficient and often require additional ... is important to establish new mechanisms by which water ...
Cached Biology News:3 prominent Cell Press journals named among the 100 most influential journals in past 100 years 2Novel lung cancer vaccine shows promise in fighting early-stage lung cancer 2Weizmann Institute scientists develop a unique approach for splitting water into hydrogen and oxygen 2Weizmann Institute scientists develop a unique approach for splitting water into hydrogen and oxygen 3
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
WTAP Antibody...
Biology Products: